ArticleOncotarget2016

eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.

Andrea Casadei Gardini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.